Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer

被引:77
|
作者
De Jaeger, K
Seppenwoolde, Y
Boersma, LJ
Muller, SH
Baas, P
Belderbos, JSA
Lebesque, JV
机构
[1] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Chest Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
pulmonary function; SPECT; perfusion; tumor response; mean lung dose;
D O I
10.1016/S0360-3016(02)04389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion. Methods and Materials: Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEVt] and diffusion capacity [T-L,T-COc]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes. Results: In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV1 (p = 0.02), but was associated with a reduction of T-L,T-COc. (P = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs. Conclusion: The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV1 and a decline of T-L,T-COc. Reperfusion was not associated with an improvement of global pulmonary function. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:1331 / 1340
页数:10
相关论文
共 50 条
  • [21] Standard of care in high-dose radiotherapy for localized non-small cell lung cancer
    De Ruysscher, Dirk
    Lambrecht, Maarten
    van Baardwijk, Angela
    Peeters, Stephanie
    Reymen, Bart
    Verhoeven, Karolien
    Wanders, Rinus
    Ollers, Michel
    van Elmpt, Wouter
    van Loon, Judith
    ACTA ONCOLOGICA, 2017, 56 (11) : 1610 - 1613
  • [22] Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer
    Gopal, R
    Starkschall, G
    Tucker, SL
    Cox, JDC
    Liao, ZX
    Hanus, M
    Kelly, JF
    Stevens, CW
    Komaki, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 114 - 120
  • [23] The role of radiotherapy in non-small-cell lung cancer
    Senan, S
    Lagerwaard, FJ
    ANNALS OF ONCOLOGY, 2005, 16 : 223 - 228
  • [24] Postoperative radiotherapy in non-small-cell lung cancer
    Kal, HB
    El Sharouni, SY
    Struikmans, H
    LANCET, 1998, 352 (9137): : 1385 - 1385
  • [25] Postoperative radiotherapy in non-small-cell lung cancer
    Klages, HT
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (03) : 134 - 135
  • [26] High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer
    Watkins, J. M.
    Wahlquist, A. E.
    Zauls, A. J.
    Fields, E. C.
    Garrett-Mayer, E.
    Aguero, E. G.
    Silvestri, G. A.
    Sharma, A. K.
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2010, 54 (06) : 554 - 561
  • [27] Radical radiotherapy in non-small-cell lung cancer
    Jovanovski, D
    Smickoska, S
    Crvenkova, S
    Stojkovski, I
    2ND BALKAN CONGRESS OF ONCOLOGY, 1999, : 303 - 308
  • [28] PHASE-II STUDY OF HIGH-DOSE EPIRUBICIN IN NON-SMALL-CELL LUNG-CANCER
    WILS, J
    UTAMA, I
    SALA, L
    SMEETS, J
    RIVA, A
    EUROPEAN JOURNAL OF CANCER, 1990, 26 (11-12) : 1140 - 1141
  • [29] Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer
    De Ruysscher, Dirk
    Dehing, Cary
    Yu, Shipeng
    Wanders, Rinus
    Ollers, Michel
    Dingemans, Anne-Marie C.
    Bootsma, Gerben
    Hochstenbag, Monique
    Geraedts, Wiel
    Pitz, Cordula
    Simons, Jean
    Boersma, Liesbeth
    Borger, Jacques
    Dekker, Andre
    Lambin, Philippe
    RADIOTHERAPY AND ONCOLOGY, 2009, 91 (03) : 353 - 359
  • [30] Hypofractionated accelerated high-dose radiotherapy (RT) in non-small cell lung cancer (NSCLC)
    Brennan, S. M.
    Fitzpatrick, D.
    Armstrong, J.
    McElroy, A.
    Dunne, M.
    Shea, C. O.
    Thirion, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)